A Phase I/II Study of the Safety of CD34+ Haematopoietic Stem/Progenitor Cells and CD4+ T Lymphocytes Transduced With LVsh5/C46, a Dual Anti-HIV Gene Transfer Construct, in HIV-1 Infected Patients With High-risk Lymphoma
Phase of Trial: Phase I/II
Latest Information Update: 25 Feb 2019
Price : $35 *
At a glance
- Drugs Cal 1 (Primary)
- Indications HIV-1 infections
- Focus Adverse reactions; Pharmacodynamics
- Acronyms GENHIV
- 18 Feb 2019 Planned End Date changed from 1 Jun 2023 to 15 Jan 2024.
- 18 Feb 2019 Planned primary completion date changed from 1 Jun 2023 to 15 Jan 2022.
- 18 Feb 2019 Status changed from not yet recruiting to recruiting.